Companies / Enveric Biosciences, Inc.

Enveric Biosciences, Inc.

Nasdaq: ENVBCIK 890821CAMBRIDGE, MA

Financials · FY2019

Revenue$39.91M
Net income$-8.77M
Total debt$1.74M
Cash$2.84M
Diluted EPS$-36.24
Shares outstanding3.7M

Ownership

3.7M shares outstanding · as of May 13, 2026
0.72%Insiders
Ownership
Insiders0.72%26,416
10%+ / strategic0.46%16,974
Institutions1.53%56,320
Public float97.29%3,582,174

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Webb Michael DDirector
0.72%26,416

Institutional holders 12

View all →
HolderValue% of shares
Geode Capital Management, LLC$62.4K0.87%
AdvisorShares Investments LLC$61.6K0.46%
UBS Group AG$10.5K0.08%
Citigroup Inc$8.3K0.06%
Tower Research Capital LLC (TRC)$7.0K0.05%
SBI Securities Co., Ltd.$178<0.01%
BlackRock, Inc.$70<0.01%
Bank of America Corp /De$18<0.01%
Group One Trading LLC$4<0.01%
National Bank of Canada /Fi$4<0.01%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jun 1, 2026Webb Michael D
Director
GrantCommon Stock$0+19K
+234.46%
26,416
0.72% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
AdvisorShares TrustPassive13G/A—16,974—
Mitchell P. KopinPassive13G———
Lind Global Fund III LPPassive13G———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ENVBCommon StockEquity29405E505BBG000BBQ281